Healthcare expenditures of older patients with AML are similar between HMA and intensive induction chemotherapy

Leuk Lymphoma. 2019 Nov;60(11):2817-2820. doi: 10.1080/10428194.2019.1605512. Epub 2019 May 6.

Authors

Curtis Lachowiez¹, Matthew Kearney¹, Gabrielle Meyers², Richard T Maziarz², Rachel J Cook²

Affiliations

¹ Department of Medicine, Oregon Health and Science University, Portland, OR, USA.
² Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.

PMID: 31056994
DOI: 10.1080/10428194.2019.1605512

No abstract available

Publication types

Letter

MeSH terms

Aged
Antimetabolites, Antineoplastic / economics
Antimetabolites, Antineoplastic / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Azacitidine / economics*
Azacitidine / therapeutic use
Combined Modality Therapy
Female
Follow-Up Studies
Health Care Costs / statistics & numerical data*
Health Expenditures / statistics & numerical data*
Hematopoietic Stem Cell Transplantation / economics
Humans
Induction Chemotherapy / economics*
Leukemia, Myeloid, Acute / economics*
Leukemia, Myeloid, Acute / mortality
Leukemia, Myeloid, Acute / therapy*
Male
Practice Patterns, Physicians' / statistics & numerical data
Prognosis
Retrospective Studies
Survival Rate

Substances

Antimetabolites, Antineoplastic
Azacitidine